Mark Cuban’s generic-drug play isn’t just another “disrupt healthcare” headline. It’s a bet on a painfully specific weak point in the pharmaceutical value chain: the moment a brand’s patent moat starts to crumble—and the market’s incentives still haven…

Biotech hiring isn’t just about growth—it’s often about patent strategy.
If you’ve been watching the market and thinking, “Why are companies suddenly hiring licensing, BD, legal ops, and IP-heavy roles?”—there’s a good chance the answer is sitting in p…

Patent cliffs don’t just arrive—they get engineered.
If you’ve worked anywhere near pharma strategy, you know the script: blockbuster patent expiration hits, revenue compresses, and the market waits for the next pipeline “big bet.” But the reality is…

Drug pricing transparency is having a moment. In boardrooms and policy circles, the argument is familiar: shine a light on how prices are set, publish the inputs, and the market will correct itself. But the thesis in the piece you should read—“Drug Pri…

Big Pharma vs. Cost-Plus: The “Strategic War” You Should Model Now
The market loves a clean story: big incumbent vs. disruptive upstart, monopoly vs. competition, high prices vs. affordability. But the reality in healthcare is rarely that simple—and th…

Pharma doesn’t just “watch” patent dates—it operates on them.
In the race to secure market exclusivity, the difference between a clean win and a costly setback can come down to something as unglamorous as an IND/CTA timeline. Yet behind the scenes, lea…

Pharma doesn’t just “watch” patent dates. It tracks them—down to the day—because in the IND-to-NDA window, timing is strategy.
Here’s the agitation: one missed milestone can cost years of exclusivity. One misread regulatory clock can turn a planned glo…

Europe’s “divisional patent” trap is one of those legal mechanisms that sounds technical—until you see what it does to patients, payers, and timelines.
Here’s the uncomfortable truth: Big Pharma can often delay generic entry without “losing in court.” …

Generic drug approvals aren’t won in the lab—they’re won in the data.
If you’ve ever watched a complex generic stall at the finish line, you already know the frustration: the science is there, the formulation is plausible, the manufacturing is solid……

How does fruit juice impact Lipitor absorption? The effectiveness of Lipitor (atorvastatin), a statin medication used to… https://www.Drugchatter.com/chat/24737/does-lipitor’s-effectiveness-vary-with-any-fruit-juice/